Payment overview · 2025
General Payments
$1,207.80
63 reported records · 24 companies
Healthcare provider profile · identity verified
Charles Brooks Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GRANBURY, TX · NPI 1790780930
Verified facts
What the public records show
CMS Open Payments records show Charles Brooks Smith, M.D. received $1,207.80 in general payments during 2025 across 63 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $208.05 | 17.2% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $192.43 | 15.9% | 14 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $143.12 | 11.8% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.25 | 8.4% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $71.42 | 5.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $69.29 | 5.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.73 | 5.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.47 | 3.5% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $29.70 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.81 | 2.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.03 | 2.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $22.86 | 1.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.26 | 1.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.82 | 1.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.55 | 1.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.89 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.49 | 1.5% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $18.29 | 1.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $17.78 | 1.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.78 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.75 | 1.4% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $16.28 | 1.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.09 | 1.3% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.66 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,207.80 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $162.75 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $127.37 | 9 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $83.50 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $71.42 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $69.29 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $60.73 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $59.22 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $58.94 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.13 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $45.30 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.88 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.60 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $29.70 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.81 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.81 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| OMNIA Normalized: omnia |
Device | Globus Medical, Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $12.01 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $8.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 126 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 175 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
175 | 51 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
126 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
110 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 676 | 213 |
| Atorvastatin Calcium | Atorvastatin Calcium | 602 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 121 |
| Lisinopril | Lisinopril | 360 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 360 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 287 | 91 |
| Alprazolam | Alprazolam | 267 | 56 |
| Gabapentin | Gabapentin | 255 | 82 |
| Losartan Potassium | Losartan Potassium | 246 | 76 |
| Metformin Hcl | Metformin Hcl | 237 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 70 |
| Trazodone Hcl | Trazodone Hcl | 209 | 56 |
| Ezetimibe | Ezetimibe | 191 | 64 |
| Simvastatin | Simvastatin | 182 | 52 |
| Celecoxib | Celecoxib | 177 | 53 |
| Synthroid | Levothyroxine Sodium | 175 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 173 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 52 |
| Montelukast Sodium | Montelukast Sodium | 157 | 52 |
| Potassium Chloride | Potassium Chloride | 152 | 46 |
| Omeprazole | Omeprazole | 151 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 48 |
| Furosemide | Furosemide | 126 | 47 |
| Ozempic | Semaglutide | 126 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 125 | 34 |
| Clonazepam | Clonazepam | 122 | 30 |
| Carvedilol | Carvedilol | 114 | 34 |
| Meloxicam | Meloxicam | 113 | 33 |
| Eliquis | Apixaban | 110 | 26 |
| Allopurinol | Allopurinol | 107 | 35 |
| Bupropion Xl | Bupropion Hcl | 107 | 30 |
| Fenofibrate | Fenofibrate | 107 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 30 |
| Valsartan | Valsartan | 97 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 27 |
| Sertraline Hcl | Sertraline Hcl | 92 | 31 |
| Eszopiclone | Eszopiclone | 91 | 31 |
| Trulicity | Dulaglutide | 91 | 16 |
| Famotidine | Famotidine | 90 | 27 |
| Estradiol | Estradiol | 89 | 33 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 82 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 29 |
| Methylprednisolone | Methylprednisolone | 74 | 62 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 25 |
| Jardiance | Empagliflozin | 62 | 22 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 20 |
| Mounjaro | Tirzepatide | 58 | 17 |
| Letrozole | Letrozole | 56 | 19 |
| Lorazepam | Lorazepam | 56 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 15 |
| Ondansetron Odt | Ondansetron | 51 | suppressed |
| Atenolol | Atenolol | 50 | 18 |
| Glimepiride | Glimepiride | 50 | 15 |
| Myrbetriq | Mirabegron | 50 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 14 |
| Progesterone | Progesterone, Micronized | 50 | 16 |
| Buspirone Hcl | Buspirone Hcl | 49 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Azithromycin | Azithromycin | 47 | 44 |
| Metformin Hcl Er | Metformin Hcl | 47 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | suppressed |
| Pregabalin | Pregabalin | 41 | 15 |
| Ramipril | Ramipril | 41 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 11 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 40 | 13 |
| Finasteride | Finasteride | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 16 |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 13 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | 13 |
| Cefdinir | Cefdinir | 25 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Np Thyroid | Thyroid,pork | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Modafinil | Modafinil | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Minoxidil | Minoxidil | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Forteo | Teriparatide | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,207.80 · 63 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE, GIVLAARI, INSPIRE, JARDIANCE, JATENZO, Jornay PM, Korlym, LEQVIO, Leqembi, NP Thyroid 60, OMNIA, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SYNTHROID, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error